(160 days)
The Philips OB TraceVue Obstetrical Information Management System is indicated for obstetric patients during and after pregnancy, who require monitoring in a healthcare setting. The Philips OB TraceVue provides: - Basic and advanced fetal trace alarming for both antepartum and intrapartum patients - Central monitoring of maternal alarming. - Documentation capabilities and data storage. - Viewing and alarming of patient physiologic data, at remote locations, via the healthcare facility web access (intra/internet).
The Philips OB TraceVue Obstetrical Information Management System is intended to acquire, present and store patient information and to document relevant monitor information (surveillance) of patients in the OB/GYN departments of healthcare facilities, as needed by healthcare professionals. It offers antepartum and intrapartum alarming and optional storage. It helps to monitor and chart the labor of patients. It can create awareness by alarming the user of suspicious traces and maternal parameters, but leaves the decision about what action to take to the clinician. Patient-related data can be stored to ensure a complete, permanent record of patient data. The device is a prescriptive device. US federal law restricts this device to sale by, or on the order of, a physician. Physical patient contact is not intended for the medical purpose of the device.
The provided text does not contain information about acceptance criteria or a study proving the device meets said criteria. The document is a 510(k) summary for the Philips OB TraceVue Obstetrical Information Management System, software revision Rev.G.00. It details modifications, intended use, and substantial equivalence to predicate devices, but it does not include performance data or studies against specific acceptance criteria.
The information provided largely focuses on the regulatory submission process, device classification, and changes to the software, particularly concerning alarming capabilities and adaptation to NICHD guidelines. There is no mention of clinical studies, sample sizes, expert ground truth adjudication, or standalone performance testing for the device's functionality.
{0}------------------------------------------------
5.0 510 (k) Summary
This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 C.F.R. §807.92.
The submitter of this premarket notification is:
Michael Asmalsky Philips Medizin Systeme Boeblingen GmbH JUL 2 3 2010 Hewlett-Packard-Str. 2 D-71034 Boeblingen, Germany
Tel: +49 7031 463-1277 Fax: +49 7031 463-2442 Email: michael.asmalsky@philips.com
This summary was prepared on January 30th, 2010.
5.1 Device The names of the devices is the Philips OB TraceVue Names Obstetrical Information Management System software revision Rev.G.00. Classification names are as follows.
| Device Panel | Classification | ProCode | Description |
|---|---|---|---|
| Obstetrical andGynecologicalMonitoringDevices | $884.2740,II | HGM | Perinatal monitoringsystem and accessories |
| CirculatorySystem Devices | $870.1100,II | DSJ | Alarm, Blood Pressure |
{1}------------------------------------------------
5.2 Subject devices
The subject device Philips OB TraceVue Obstetrical Information Management System, software revision Rev.G.00 is substantially equivalent to to the previously cleared Philips OB TraceVue Obstetrical Information Management System Rev. F.00 (K081203, 28th 2008) and the Philips Avalon May -Fetal FM30, FM40 and Monitors FM20, FM50 K071800 27th 2007) and the Philips M3290A (September Intellivue Information Center Software Release E.1 K031403 (May 30th 2003) and Software release G.00 K050742 (April 05th 2005)
5.3 Modifications
The modifications of the Philips OB TraceVue Obstetrical Information Management System, software revision Rev.G.00 are only software modifications and cover:
- the capability for authorized healthcare professionals to configure the generation of alarms from maternal parameters, starting with maternal non-invasive blood pressure.
- The adaptation to settings described in the NICHD April 2008 workshop report on Electronic Fetal Monitoring. This includes a small adaptation in the system setup settings of the CTG module and the generation of contraction alarms within the intrapartum part of the alarming module
- the capability for healthcare professionals to configure the complementary viewing and alarming patient physiological data at of of remote locations, using the hospitals web access (hospital intra/internet).
All other measurement parameters that contain signal acquisition and/or physiological algorithms are unchanged in this Premarket Notification.
The before described modifications are reflected in the updated instructions for use and in the updated technical data sheets. The updated instructions for use also contain other minor improvements due to latest findings and suggestions. The current drafts of both documents are attached in Annex A of this submission.
Improvements that are purely data management improvements in the meaning of the Draft Proposed Rules Docket No. 2007N-0484, CDRH 200553 Devices: General Hospital and Personal Use Devices; Reclassification of Medical Device Data System, published February 8th, 2008 are not considered in
... 1-
{2}------------------------------------------------
this notification.
5.4 Intended Üse .
Details in the intended use of the subject device, as described in the labeling, have changed. The has been editorially clarified. wording The product itself has been modified slightly.
the added intended use of Excluding creating awareness by alarming the user of suspicious maternal parameters, the intended use is the same as previously cleared for the legally marketed predicate device Philips OB TraceVue Obstetrical Information Management System Rev. F.00 (K081203 May 28th 2008)
Intended Use:
The Philips OB TraceVue Obstetrical Information Management System
is intended to acquire, present and store patient information and to document relevant monitor information (surveillance) of patients in the OB/GYN departments of healthcare facilities, as needed by healthcare professionals.
It offers antepartum and intrapartum alarming and optional storage. It helps to monitor and chart the labor of patients.
It can create awareness by alarming the user of suspicious traces and maternal parameters, but leaves the decision about what action to take to the clinician.
Patient-related data can be stored to ensure a complete, permanent record of patient data.
The device is a prescriptive device. US federal law restricts this device to sale by, or on the order of, a physician. Physical patient contact is not intended for the medical purpose of the device.
A table of comparison of the updated and clarified wording and the original wording is provided in section 12 Substantial Equivalence discussion.
5.5 Technological Characteristics
The fundamental scientific technology employed in the operation of the Philips OB TraceVue Obstetrical Information Management System software revision Rev.G.00 has not changed from that of the predicate devices as a result of the modification.
{3}------------------------------------------------
Image /page/3/Picture/0 description: The image shows a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the edge. Inside the circle is an emblem of an eagle with its wings spread, stylized with three parallel lines forming each wing. The image is black and white and appears to be a scan or photocopy.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002
Mr. Michael Asmalsky Sr. Regulatory Affairs Engineer Philips Medizin Systeme Boeblingen GmbH Hewlett-Packard-Str. 2 BOEBLINGEN GERMANY d-71034
JUL 2 3 2010
Re: K100420
Trade/Device Name: Philips OB TraceVue Rev.G.00 Regulation Number: 21 CFR& 884.2740 Regulation Name: Perinatal monitoring system and accessories Regulatory Class: II Product Code: HGM, DSJ Dated: July 16, 2010 Received: July 21, 2010
Dear Mr. Asmalsky:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related
{4}------------------------------------------------
Page 2 -
adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Janine M. Morris
Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
Indications for Use
510(k) Number (if known): ≤ 100420_
Device Name:
Philips OB TraceVue Rev.G.00
Indications for Use
The Philips OB TraceVue Obstetrical Information Management System is indicated for obstetric patients during and after pregnancy, who require monitoring in a healthcare setting
The Philips OB TraceVue provides :
- Basic and advanced fetal trace alarming for both antepartum and . intrapartum patients
- . Central monitoring of maternal alarming.
- Documentation capabilities and data storage. .
- Viewing and alarming of patient physiologic data, at remote locations, via the healthcare facility web access (intra/internet).
Prescription Use _ Yes (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use No (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE
OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Hebert Heun
(Division Sign-Off) (Division Sign of Reproductive, Abdominal, and Radiological Device 510(k) Number
§ 884.2740 Perinatal monitoring system and accessories.
(a)
Identification. A perinatal monitoring system is a device used to show graphically the relationship between maternal labor and the fetal heart rate by means of combining and coordinating uterine contraction and fetal heart monitors with appropriate displays of the well-being of the fetus during pregnancy, labor, and delivery. This generic type of device may include any of the devices subject to §§ 884.2600, 884.2640, 884.2660, 884.2675, 884.2700, and 884.2720. This generic type of device may include the following accessories: Central monitoring system and remote repeaters, signal analysis and display equipment, patient and equipment supports, and component parts.(b)
Classification. Class II (performance standards).